HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Cosmetics Director Katz Cites Fragrance Allergens, Talc-Containing Products Among Priorities

Executive Summary

Linda Katz, director of the US FDA’s Office of Cosmetics and Colors, offered insight into priority cosmetics issues at the Independent Beauty Association’s virtual FDA Cosmetic Regulations Workshop.

You may also be interested in...



US FDA Support For Cosmetic Allergen Labeling Has Foundation In Consumers' ‘Right To Know’

Office of Cosmetics and Colors Linda Katz emphasizes FDA sees allergen labeling as a public health issue. While many allergic reactions are minor, “consumers who are extremely or exclusively sensitive to a particular ingredient should have a right to know.”

US FDA Pushing For Cosmetics Industry Cooperation On Allergens, Other Priorities

The FDA’s Center for Food Safety and Applied Nutrition has a wish list for cosmetics reform legislation, but with Congress currently focused elsewhere, the agency is using its existing authority and resources to address cosmetics safety priorities while working to drive voluntary industry support.

ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC

South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS150546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel